Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/PTPRC_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PTPRC_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PTPRC_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PTPRC_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PTPRC_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00028212 | Cervix | HSIL_HPV | positive regulation of adaptive immune response | 11/737 | 112/18723 | 4.65e-03 | 3.87e-02 | 11 |
GO:0060759 | Cervix | HSIL_HPV | regulation of response to cytokine stimulus | 14/737 | 162/18723 | 4.88e-03 | 4.02e-02 | 14 |
GO:00455801 | Cervix | HSIL_HPV | regulation of T cell differentiation | 13/737 | 146/18723 | 5.11e-03 | 4.14e-02 | 13 |
GO:000271112 | Cervix | HSIL_HPV | positive regulation of T cell mediated immunity | 7/737 | 56/18723 | 6.17e-03 | 4.81e-02 | 7 |
GO:0001959 | Cervix | HSIL_HPV | regulation of cytokine-mediated signaling pathway | 13/737 | 150/18723 | 6.39e-03 | 4.96e-02 | 13 |
GO:200123325 | Cervix | N_HPV | regulation of apoptotic signaling pathway | 36/534 | 356/18723 | 4.95e-11 | 5.63e-08 | 36 |
GO:005123524 | Cervix | N_HPV | maintenance of location | 33/534 | 327/18723 | 3.40e-10 | 2.21e-07 | 33 |
GO:00024432 | Cervix | N_HPV | leukocyte mediated immunity | 39/534 | 440/18723 | 3.94e-10 | 2.24e-07 | 39 |
GO:000715922 | Cervix | N_HPV | leukocyte cell-cell adhesion | 34/534 | 371/18723 | 2.31e-09 | 7.88e-07 | 34 |
GO:005165124 | Cervix | N_HPV | maintenance of location in cell | 25/534 | 214/18723 | 2.49e-09 | 7.88e-07 | 25 |
GO:000695921 | Cervix | N_HPV | humoral immune response | 31/534 | 317/18723 | 2.53e-09 | 7.88e-07 | 31 |
GO:000246021 | Cervix | N_HPV | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 33/534 | 356/18723 | 2.99e-09 | 8.02e-07 | 33 |
GO:004211022 | Cervix | N_HPV | T cell activation | 39/534 | 487/18723 | 7.04e-09 | 1.58e-06 | 39 |
GO:000181922 | Cervix | N_HPV | positive regulation of cytokine production | 38/534 | 467/18723 | 7.18e-09 | 1.58e-06 | 38 |
GO:000244911 | Cervix | N_HPV | lymphocyte mediated immunity | 32/534 | 350/18723 | 7.29e-09 | 1.58e-06 | 32 |
GO:000190621 | Cervix | N_HPV | cell killing | 22/534 | 188/18723 | 2.20e-08 | 3.03e-06 | 22 |
GO:000269621 | Cervix | N_HPV | positive regulation of leukocyte activation | 34/534 | 409/18723 | 2.69e-08 | 3.40e-06 | 34 |
GO:005086721 | Cervix | N_HPV | positive regulation of cell activation | 34/534 | 420/18723 | 5.14e-08 | 5.59e-06 | 34 |
GO:000276421 | Cervix | N_HPV | immune response-regulating signaling pathway | 36/534 | 468/18723 | 7.52e-08 | 7.81e-06 | 36 |
GO:002240723 | Cervix | N_HPV | regulation of cell-cell adhesion | 35/534 | 448/18723 | 7.85e-08 | 7.94e-06 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTPRC | SNV | Missense_Mutation | | c.794N>A | p.Cys265Tyr | p.C265Y | | protein_coding | tolerated(0.08) | possibly_damaging(0.9) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTPRC | SNV | Missense_Mutation | | c.2299N>T | p.Pro767Ser | p.P767S | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTPRC | SNV | Missense_Mutation | | c.448N>A | p.Gly150Arg | p.G150R | | protein_coding | tolerated(0.11) | possibly_damaging(0.486) | TCGA-AC-A2FM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PTPRC | SNV | Missense_Mutation | novel | c.977A>C | p.Lys326Thr | p.K326T | | protein_coding | tolerated(0.35) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTPRC | SNV | Missense_Mutation | novel | c.319N>T | p.Pro107Ser | p.P107S | | protein_coding | tolerated(0.07) | benign(0.015) | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PTPRC | SNV | Missense_Mutation | | c.1538N>A | p.Gly513Asp | p.G513D | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PTPRC | SNV | Missense_Mutation | rs758824419 | c.2695N>A | p.Glu899Lys | p.E899K | | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PTPRC | SNV | Missense_Mutation | novel | c.2476N>C | p.Glu826Gln | p.E826Q | | protein_coding | deleterious(0.01) | possibly_damaging(0.669) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
PTPRC | SNV | Missense_Mutation | | c.3337N>A | p.Asp1113Asn | p.D1113N | | protein_coding | deleterious(0) | possibly_damaging(0.88) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PTPRC | SNV | Missense_Mutation | | c.308N>T | p.Ser103Leu | p.S103L | | protein_coding | tolerated(0.73) | benign(0.084) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | [131I]-BC8 | | |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | HYDROGEN PEROXIDE | HYDROGEN PEROXIDE | 15012988 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | PREDNISONE | PREDNISONE | 17063711 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | ERYTHROPOIETIN | EPOETIN BETA | 1713254 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | GM-CSF/IL-3 FUSION PROTEIN | | 1713254 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | etanercept | ETANERCEPT | 20309874,23007924 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | VACCINE | | 12007880 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | adalimumab | ADALIMUMAB | 20309874,23007924 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | PROTEIN KINASE INHIBITOR | | 9473774 |
5788 | PTPRC | CLINICALLY ACTIONABLE, TUMOR SUPPRESSOR, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, DRUGGABLE GENOME, PROTEIN PHOSPHATASE, KINASE | | LM-CD45 | | |